- About ASF
- What is Autism?
- How Common is Autism?
- Signs and Symptoms of Autism
- Autism Diagnosis
- Following a Diagnosis
- Treatment Options
- Beware of Non-Evidence-Based Treatments
- Statement on Use of Medical Marijuana for People with Autism
- Statement on Use of Applied Behavior Analysis (ABA) for Autism
- Autism and Vaccines
- Autism Science
- Autism Research Strategic Plan
- Research by Topic
- Research by Year
- Interviews with Scientists
- Science Journals
- Autism in the News
- Recommended Reading
- Year End Summaries
- Participate in Research
- NIH ACE Grants
- NIMH Resources
- Autism Research Glossary
- Quick Facts About Autism
- What We Fund
- Funding Calendar
- ASF Funded Research
- Where Are They Now?
- ASF Supported Findings
- Autism Sisters Project
- Baby Siblings Research Consortium
- Get Involved
- Resources for Grantees
- Resources for Families
- Sam’s Sibs Stick Together
- COVID-19 Resources
- Day of Learning
- Contact Us
Research by Topic: Rett Syndrome
Today, ASF announced that it will be leading the newly-launched Alliance for Genetic Etiologies of Neurodevelopmental Disorders and Autism (AGENDA). This alliance is a partnership of research and advocacy organizations focused on improving outcomes of individuals with all forms of autism by fostering a genetics-first approach to autism science. AGENDA will also work to strengthen […]
Filed under: ASD, asf, Autism, collaboration, database, dup15q, Dup15q Alliance, featured, fragile X syndrome, FRAXA, FRAXA Research Foundation, genetic, Phelan-McDermid Syndrome, Phelan-Mcdermid Syndrome Foundation, PMSF, registry, research, Rett Syndrome, Rett Syndrome Research Trust, RSRT, science, SFARI, Simons Foundation, Simons VIP, subtypes, TSA, Tuberous Sclerosis, Tuberous Sclerosis Alliance
On Friday, February 19, the NIH organized a workshop on regression in autism. It included autism researchers as well as neurobiologists studying regression in other disorders, specifically Rett Syndrome. Rett Syndrome is characterized by a regression in symptoms around 18-30 months of age but is the result of a known genetic mutation. Because the genetic mutation […]
The motor problems seen in Rett syndrome may be the result of deficits in a pathway that mediates reward in the striatum, a brain region that coordinates movement, according to a study published in Brain Structure and Function. Studies have shown that loss of MeCP2 in the front of the brain is sufficient to lead to Rett-like symptoms in mice. The forebrain includes the striatum, which integrates information from other brain regions to help plan and coordinate movement. The new study found that mice that model Rett syndrome have significantly less dopamine a chemical messenger that mediates reward in the striatum than controls do. The study suggests that changes in dopamine levels influence neural circuits in the striatum that regulate motor function.
Professor Monica Justice has written a study on a connection between cholesterol and Rett Syndrome. Statin drugs, known to lower cholesterol, were shown to increase mobility, overall health scores, and lifespan in mice with Rett Syndrome.
Two collaborative papers reveal the key steps of how mutations to the MeCP2 gene cause Rett Syndrome by impairing the interaction between MeCP2 and the NCoR/SMRT co-repressor.
Scientists reveal efforts to create transgenic monkey models of autism. Compared to mice and rats, these animals are more genetically similar to humans, and display more complex social and communicative behaviors.
Researchers led by Dr. Ben Philpot, an ASF funded mentor, at UNC School of Medicine found that seizures in individuals with Angelman syndrome could be linked to an imbalance in brain cell activity. Angelman syndrome exhibits frequent comorbidity with autism spectrum disorders.
A bone-marrow transplant can treat a mouse version of Rett syndrome, a severe autism spectrum disorder that affects roughly 1 in 10,00020,000 girls born worldwide (boys with the disease typically die within a few weeks of birth).
Brain-Derived Neurotrophic Factor: Finding May Have Implications for Rett Syndrome, Other Neurological DisordersPublished January 27, 2012 in Science Daily
Researchers at Oregon Health & Science University have discovered that a molecule critical to the development and plasticity of nerve cells — brain-derived neurotrophic factor (BDNF) — is severely lacking in brainstem neurons in mutations leading to Rett syndrome, a neurological developmental disorder.
A collaborative effort between researchers at the Salk Institute for Biological Studies and the University of California, San Diego, successfully used human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome to replicate autism in the lab and study the molecular pathogenesis of the disease.
A team from the University of California, San Diego, and the Salk Institute for Biological Studies devised a way to study brain cells from patients with autism, and found a way reverse cellular abnormalities in neurons that have been associated with autism, specifically Rett Syndrome.
In 1999, Baylor College of Medicine researcher Dr. Huda Zoghbi and her colleagues identified mutations in the gene called MECP2 as the culprit in a devastating neurological disorder called Rett syndrome . In new research in mice published in the current issue of the journal Nature, Zoghbi and her colleagues demonstrate that the loss of the protein MeCP2 in a special group of inhibitory nerve cells in the brain reproduces nearly all Rett syndrome features.
A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem CellsPublished November 1, 2010 in Cell, Marchetto et al
Autism spectrum disorders (ASD) are complex neurodevelopmental diseases in which different combinations of genetic mutations may contribute to the phenotype. Using Rett syndrome (RTT) as an ASD genetic model, we recapitulate early stages of a human neurodevelopmental disease, using induced pluripotent stem cells (iPSCs) from RTT patients' fibroblasts, which essentially creates a "disease in a […]
A group of researchers at the University of Bristol have sequestered the potentially fatal breath holding episodes associated with the autistic-spectrum disorder Rett syndrome. Using a unique combination of drugs, they have discovered that the area of the brain that allows breathing to persist throughout life without interruption has reduced levels of a transmitter substance called aminobutyric acid.
Rett Syndrome (RTT) is a severe form of X-linked mental retardation caused by mutations in the gene coding for methyl CpG-binding protein 2 (MECP2). Mice deficient in MeCP2 have a range of physiological and neurological abnormalities that mimic the human syndrome. Here we show that systemic treatment of MeCP2 mutant mice with an active peptide […]
Mutations in the gene encoding the transcriptional repressor methyl-CpG binding protein 2 (MeCP2) cause the neurodevelopmental disorder Rett syndrome. Loss of function as well as increased dosage of the MECP2 gene cause a host of neuropsychiatric disorders. To explore the molecular mechanism(s) underlying these disorders, we examined gene expression patterns in the hypothalamus of mice […]